Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
2 (100.0%)Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Anelixis Therapeutics, LLC
- Registration Number
- NCT04711226
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Multiple Doses of AT-1501-A201 in Adults With ALS
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Anelixis Therapeutics, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT04322149
- Locations
- 🇺🇸
Barrows Neurological Institute, Phoenix, Arizona, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸California Pacific Medical Center, San Francisco, California, United States
News
No news found